Wnt/beta-catenin signaling pathway: multiple roles in osteosarcoma, bone remodeling and angiogenesis

doi:10.3969/j.issn.2095-4344.2871

Abstract

Abstract:

BACKGROUND: The Wnt/β-catenin signaling pathway plays a key role in osteosarcoma tumorigenesis and bone remodeling, and its roles in angiogenesis and immune surveillance are the two key mechanisms of metastatic dissemination.

OBJECTIVE: To review the role of Wnt/β-catenin pathway in the occurrence and development of osteosarcoma and its regulatory role in specific microenvironment.

METHODS: PubMed database was searched for relevant articles on the relationship between Wnt/β-catenin pathway and bone tumors using the search terms of “Wnt/β-catenin; bone tumors.” The search time for publications was from 2000 to 2020.

RESULTS AND CONCLUSION: The typical Wnt/β-catenin signaling pathway plays an important role in the growth and metastasis of osteosarcoma by directly acting on osteosarcoma cells and indirectly regulating cell activity in osteosarcoma. The Wnt/β-catenin pathway also participates in the hijacking of the bone tumor microenvironment by osteosarcoma cells, promotes the regulation of extracellular matrix, makes the tumor cells invasive, induces immune tolerance and angiogenesis in tumor cells, and eventually augments metastatic spread. In addition, the typical Wnt signaling pathway abnormally activated in osteosarcoma cells seems to be closely related to cell proliferation, induction of epithelial-mesenchymal transition-like processes, acquisition of osteosarcoma-promoting tumor cell stem cell characteristics, and metastatic spread.

Key words: Wnt/β-catenin, osteosarcoma, bone tumor microenvironment, treatment strategy, pathway, review

CLC Number:

Liu Chang, Song Keguan. Wnt/beta-catenin signaling pathway: multiple roles in osteosarcoma, bone remodeling and angiogenesis[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(32): 5213-5220.

Figures/Tables 2

References

[1] STRAUSS SJ, WHELAN JS. Current questions in bone sarcomas. Curr Opin Oncol.2018;30:252-259.

[2] LU P, WEAVER VM, WERB Z. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol.2012; 196:395-406.

[3] CRENN V, BITEAU K, AMIAUD J, et al.Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: Retrospective analysis and preclinical modeling. Am J Cancer Res.2017;7:2333-2349.

[4] ALFRANCA A, MARTINEZ-CRUZADO L, TORNIN J, et al.Bone microenvironment signals in osteosarcoma development.Cell Mol Life Sci.2015;72:3097-3113.

[5] JIN H, BARROTT JJ, CABLE MG, et al. The Impact of Microenvironment on the Synovial Sarcoma Transcriptome.Cancer Microenviron.2017;10:1-7.

[6] GOLDSTEIN SD, HAYASHI M, ALBERT CM, et al. An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis.Clin Exp Metastasis.2015;32:703-715.

[7] RIEMANN A, SCHNEIDER B, GÜNDEL D, et al .Acidosis Promotes Metastasis Formation by Enhancing Tumor Cell Motility. Adv Exp Med Biol.2016;876:215-220.

[8] CHATTOPADHYAY S, CHAKLADER M, CHATTERJEE R,et al. Differential expression of mitotic regulators and tumor microenvironment influences the regional growth pattern of solid sarcoma along the cranio-caudal axis.Exp Cell Res. 2016;340:91-101.

[9] LAMOUREUX F, RICHARD P, WITTRANT Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res.2007;67:7308-7318.

[10] DASS CR, CHOONG PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model.Mol Cancer Ther.2007;6: 3263-3270.

[11] HAN Y, WU C, WANG J, et al. CXCR7 maintains osteosarcoma invasion after CXCR4 suppression in bone marrow microenvironment. Tumour Biol. 2017;39:101042831770163.

[12] CORTINI M, MASSA A, AVNET S, et al. Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion.PLoS ONE.2016;11: e0166500.

[13] QI J, ZHOU Y, JIAO Z, et al. Exosomes Derived from Human Bone Marrow Mesenchymal Stem Cells Promote Tumor Growth Through Hedgehog Signaling Pathway.Cell Physiol Biochem. 2017;42:2242-2254.

[14] WANG Y, CHU Y, YUE B, et al. Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway.Oncotarget.2017;8:23803-23816.

[15] HEYMANN MF, LÉZOT F, HEYMANN D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma.Cell Immunol. 2019;343:103711.

[16] NOY R, POLLARD JW.Tumor-associated macrophages: From mechanisms to therapy.Immunity.2014;41:49-61.

[17] GOMEZ-BROUCHET A, ILLAC C, GILHODES J, et al. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial.Oncoimmunology.2017;6:e1331193.

[18] DUMARS C, NGYUEN JM, GAULTIER A, et al.Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.Oncotarget.2016;7:78343-78354.

[19] ZHOU Q, XIAN M, XIANG S, et al.All Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor- Associated Macrophages.Cancer Immunol Res.2017;5:547-559.

[20] HAN Q, SHI H, LIU F. CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol. 2016;34:101-106.

[21] CHANG CH, QIU J, O’SULLIVAN D, et al.Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell.2015;162:1229-1241.

[22] LEWIS DM, PRUITT H, JAIN N, et al.A Feedback Loop between Hypoxia and Matrix Stress Relaxation Increases Oxygen-Axis Migration and Metastasis in Sarcoma.Cancer Res. 2019;79: 1981-1995.

[23] ITOH H, KADOMATSU T, TANOUE H, et al. TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.Oncogene. 2018;37: 2903-2920.

[24] PIPERNO-NEUMANN S, LE DELEY MC, RÉDINI F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): A randomised, multicentre, open-label, phase 3 trial.Lancet Oncol.2016;17:1070-1080.

[25] DUCHARTRE Y, KIM YM, KAHN M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol.2016;99: 141-149.

[26] ZHAN T, RINDTORFF N, BOUTROS M. Wnt signaling in cancer. Oncogene.2017;36:1461-1473.

[27] HARB J, LIN PJ, HAO J. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics. Curr Oncol Rep. 2019;21:12.

[28] KAHN M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513-532.

[29] CHEN C, ZHAO M, TIAN A, et al.Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells.Oncotarget. 2015;6:17570-17583.

[30] LU Y, GUAN GF, CHEN J,e t al.Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival.Oncol Lett.2015;10:2123–2129.

[31] CAI Y, MOHSENY AB, KARPERIEN M, et al. Inactive Wnt/beta- catenin pathway in conventional high-grade osteosarcoma.J Pathol. 2010;220:24-33.

[32] SHIMOZAKI S,YAMAMOTO N, DOMOTO T, et al. Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin.Oncotarget.2016;7:77038-77051.

[33] JIE XX, ZHANG XY, XU CJ. Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications. Oncotarget 2017;8:81558-81571.

[34] YANG G, YUAN J, LI K. EMT transcription factors: Implication in osteosarcoma.Med Oncol.2013;30: 697.

[35] VERRECCHIA F, RÉDINI F. Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment.Front Oncol. 2018;8:133.

[36] FUXE J, VINCENT T, DE GARCIA HERREROS A. Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle. 2010;9:2363-2374.

[37] TIAN H, ZHOU T, CHEN H, et al. Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway.J Orthop Res.2019;37: 1638-1648.

[38] WANG S, ZHANG D, HAN S, et al.Fibulin-3 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition and activating the Wnt/β-catenin signaling pathway.Sci Rep.2017; 7:6215.

[39] FAN S, GAO X, CHEN P, et al. Carboxypeptidase E-ΔN promotes migration, invasiveness, and epithelial mesenchymal transition of human osteosarcoma cells via the Wnt-β-catenin pathway. Biochem. Cell Biol.2018:1-8.

[40] ZENG Q, LI Z, ZHAO X, et al. Ubiquitin-specific protease 7 promotes osteosarcoma cell metastasis by inducing epithelial-mesenchymal transition. Oncol Rep.2019;41:543-551.

[41] CAI Z, CAO Y, LUO Y, et al. Signalling mechanism(s) of epithelial-mesenchymal transition and cancer stem cells in tumour therapeutic resistance.Clin Chim Acta.2018;483:156-163.

[42] TAKEBE N, MIELE L, HARRIS PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin Oncol.2015;12:445-464.

[43] ADHIKARI AS, AGARWAL N, WOOD BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.Cancer Res. 2010;70:4602-4612.

[44] MARTINS-NEVES SR, CORVER WE, PAIVA-OLIVEIRA DI, et al. Osteosarcoma Stem Cells Have Active Wnt/β- catenin and Overexpress SOX2 and KLF4.J Cell Physiol.2016;231:876-886.

[45] LIU Y, WANG Y, YANG H, et al. MicroRNA-873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β-catenin pathway.Int J Oncol.2019;54:1809-1820.

[46] CAI W, XU Y, YIN J, et al. miR-552-5p facilitates osteosarcoma cell proliferation and metastasis by targeting WIF1. Exp Ther Med.2019;17:3781-3788.

[47] LIU Y, BAO Z, TIAN W, et al. miR-885-5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β-catenin.Oncol Lett.2019;17:1996-2004.

[48] REN J, YANG M, XU F, et al.microRNA-758 inhibits the malignant phenotype of osteosarcoma cells by directly targeting HMGA1 and deactivating the Wnt/β-catenin pathway.Am J Cancer Res. 2019;9: 36-52.

[49] XIA P, GU R, ZHANG W, et al.MicroRNA-377 exerts a potent suppressive role in osteosarcoma through the involvement of the histone acetyltransferase 1-mediated Wnt axis.J Cell Physiol. 2019;234(12):22787-22798.

[50] LI C, WANG F, WEI B, et al. LncRNA AWPPH promotes osteosarcoma progression via activation of Wnt/β-catenin pathway through modulating miR-93-3p/FZD7 axis. Biochem. Biophys. Res Commun.2019;514: 1017-1022.

[51] BROWN HK, SCHIAVONE K, GOUIN F, et al.Biology of Bone Sarcomas and New Therapeutic Developments. Calcif Tissue Int. 2018;102:174-195.

[52] PEDERSON L, RUAN M, WESTENDORF JJ, et al.Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci.USA 2008;105: 20764-20769.

[53] WEIVODA MM, RUAN M, HACHFELD CM, et al.Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways.J Bone Miner Res.2016; 31:65-75.

[54] SADANANDAM A, FUTAKUCHI M, LYSSIOTIS CA, et al.A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling. BMC Cancer.2011; 11:304.

[55] BU G, LU W,LIU CC, et al.Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases.Int J Cancer.2008; 123:1034-1042.

[56] BJØRNLAND K, FLATMARK K, PETTERSEN S,et al.Matrix metalloproteinases participate in osteosarcoma invasion.J Surg Res.2005;127:151-156.

[57] KUNZ P, SÄHR H, LEHNER B, et al. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma.BMC Cancer.2016;16:223.

[58] GUO Y, ZI X, KOONTZ Z, et al.Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells.J Orthop Res.2007;25:964-971.

[59] LIU B, LI G, WANG X, et al.A furin inhibitor downregulates osteosarcoma cell migration by downregulating the expression levels of MT1-MMP via the Wnt signaling pathway.Oncol Lett. 2014;7: 1033-1038.

[60] OLSEN JJ, POHL SÖ, DESHMUKH A, et al.The Role of Wnt Signalling in Angiogenesis. Clin Biochem Rev. 2017;38;131-142.

[61] CARMELIET P, JAIN RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.Nat Rev Drug Discov.2011;10:417-427.

[62] MAVROGENIS AF, VOTTIS CT, MEGALOIKONOMOS PD, et al. Neovascularization in Ewing’s sarcoma. Neoplasma.2018;65: 317-325.

[63] CHEN D, ZHANG YJ, ZHU K, et al. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.Tumour Biol.2013;34: 1895-1899.

[64] YANG J, YANG D, SUN Y, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA,in human osteosarcoma.Cancer.2011;117: 4925-4938.

[65] EASWARAN V, LEE SH, INGE L, et al.beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res.2003;63:3145-3153.

[66] KAWANO Y, KYPTA R. Secreted antagonists of the Wnt signalling pathway.J Cell Sci.2003;116: 2627-2634.

[67] DUFOURCQ P, LEROUX L, EZAN J, et al. Regulation of endothelial cell cytoskeletal reorganization by a secreted frizzled- related protein-1 and frizzled 4- and frizzled 7-dependent pathway: Role in neovessel formation.Am J Pathol.2008;172:37-49.

[68] MULEY A, MAJUMDER S, KOLLURU GK, et al. Secreted frizzled-related protein 4: An angiogenesis inhibitor. Am J Pathol. 2010;176:1505-1516.

[69] ZHAO S, KURENBEKOVA L, GAO Y, et al.NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma.Oncogene.2015;34:5069.

[70] LIAO D, JOHNSON RS. Hypoxia: A key regulator of angiogenesis in cancer.Cancer Metastasis Rev. 2007; 26;281-290.

[71] KROCK BL, SKULI N, SIMON MC. Hypoxia-induced angiogenesis: Good and evil.Genes Cancer.2011;2: 1117-1133.

[72] ZHANG XD, WU Q, YANG SH.Effects of siRNA-mediated HIF-1α gene silencing on angiogenesis in osteosarcoma. Pak J Med Sci. 2017;33:341-346.

[73] ZHANG B, LI YL, ZHAO JL, et al.Hypoxia-inducible factor-1 promotes cancer progression through activating AKT/Cyclin D1 signaling pathway in osteosarcoma. Biomed Pharmacother.2018; 105:1-9.

[74] LI Y, ZHANG W, LI S, et al. Prognosis value of Hypoxia-inducible factor-1α expression in patients with bone and soft tissue sarcoma: A meta-analysis.Springerplus.2016;5:1370.

[75] DEMIR R, DIMMLER A, NASCHBERGER E, et al. Malignant progression of invasive tumour cells seen in hypoxia present an accumulation of beta-catenin in the nucleus at the tumour front. Exp Mol Pathol. 2009;87:109-116.

[76] KAIDI A, WILLIAMS AC, PARASKEVA C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol.2007;9:210-217.

[77] SCHOLTEN DJ 2ND, TIMMER CM, PEACOCK JD, et al.Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells.PLoS ONE. 2014; 9:e111431.

[78] QIAN BZ, POLLARD JW. Macrophage diversity enhances tumor progression and metastasis.Cell.2010; 141:39-51.

[79] YANG Y, YE YC, CHEN Y, et al.Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors.Cell Death Dis.2018;9:793.

[80] LIU T, FANG XC, DING Z, et al.Pre-operative lymphocyte-to- monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma. FEBS Open Bio.2015;5:682-687.

[81] ASSAL A, KANER J, PENDURTI G, et al.Emerging targets in cancer immunotherapy: Beyond CTLA-4 and PD-1. Immunotherapy. 2015;7:1169-1186.

[82] KOIRALA P, ROTH ME, GILL J, et al. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival.Sci Rep.2016;6:31154.

[83] KOIRALA P, ROTH ME, GILL J, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.Sci Rep.2016;6:30093.

[84] WANG L, ZHANG Q, CHEN W, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.PLoS ONE.2013;8:e70689.

[85] LUKE JJ, BAO R, SWEIS RF, et al. Wnt/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res.2019;25:3074-3083.

[86] SPRANGER S, BAO R, GAJEWSKI TF.Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.Nature. 2015; 523:231-235.

[87] DE RUIZ GALARRETA M, BRESNAHAN E, MOLINA-SANCHEZ P, et al.β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124-1141.

[88] DHUPKAR P, GORDON N, STEWART J, et al.Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.Cancer Med.2018;7: 2654-2664.

[89] GALLUZZI L, SPRANGER S, FUCHS E, et al.WNT Signaling in Cancer Immunosurveillance.Trends Cell Biol. 2019;29:44-65.